U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07155031) titled 'Biotin-Acridine Red Cell Exchange Kinetics' on Aug. 27.
Brief Summary: The primary objective of the study is to describe the recovery and survival of pathogen-reduced (PR) red blood cells (RBCs) prepared and stored with the INTERCEPT Blood System for RBCs(R) (hereafter referred to as INTERCEPT RBCs) in patients with sickle cell disease (SCD) undergoing red cell exchange (RCE) therapy, utilizing flow cytometry for biotin and acridine RBC surface markers.
Study Start Date: Oct. 15
Study Type: INTERVENTIONAL
Condition:
Sickle Cell Disease
Intervention:
DEVICE: Pathogen reduced red blood cells
pathogen reduced red blood cells wit...